PHAR Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. Th…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema | ||
 Pharming Group (PHAR) Expands Joenja’s Pediatric Label. Can Growth Offset RUCONEST Weakness? Pharming Group N.V. (NASDAQ:PHAR) announced on September 11 that the U.S. Food and Drug Administration approved Joenja for children aged 4–11 with activated PI3K delta syndrome, or APDS, who weigh at least 27 kilograms. APDS disrupts immune function. The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The […] | ||
 Pharming Group (ENXTAM:PHARM) Could Be 63% Undervalued After Guidance Cut And Half Year Results Pharming Group guidance cut and half year results draw investor focus Pharming Group (ENXTAM:PHARM) has drawn fresh attention after lowering its 2026 revenue guidance by US$30 million and reporting half year 2026 results that showed reduced sales but a smaller net loss. See our latest analysis for Pharming Group. Pharming Group’s guidance cut and half year 2026 results appear to have fed into weaker sentiment, with the stock’s share price down 26.76% over 30 days and a 1 year total... | ||
Pharming Group (PHGUF) (Q2 2026) Earnings Call Highlights: Joenja Surges 40% as Ruconest Faces ... Pharming Group (PHGUF) navigates a mixed quarter with strong Joenja growth and cost discipline, offset by Ruconest revenue declines and a lowered full-year outlook. | ||
 Pharming Group Q2 Earnings Call Highlights Pharming Group (NASDAQ:PHAR) reported second-quarter revenue of $90.2 million, down 3% from a year earlier, as growth from its Joenja treatment partly offset lower sales of hereditary angioedema therapy RUCONEST. The company reduced its full-year revenue outlook by $30 million but said it expects RU | ||